Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 3B Clinical benefit achieved from subsequent lines of endocrine therapy in patients with clinical benefit to 1st line endocrine therapy

From: "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer

Lines of Endocrine therapy 2 nd line 3 rd line 4 th line
N 68 23 5
N of CB (%) 47 (69.1) 10 (43.5) 1(20.0)
Median DOR with CB (months) 12.0+(7–81) 11.0 (8–32) 15.0
N still receiving treatment 17 0 0
  1. + = including patients who are still on treatment, therefore would have additional duration of response on a later analysis; CB = Clinical Benefit; DOR = Duration of Response